FDMT 4D Molecular Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1650648 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY79,952.5%
TTM net income YoY4.2%
TTM EPS YoY28.0%
Revenue 3-yr CAGR63.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-226.0%
Net margin-208.6%
FCF margin—
EBITDA margin-220.9%
Returns
ROE-56.7%
ROA-47.0%
ROIC (approx.)-53.7%
Asset turnover0.23x
Leverage & solvency
Liabilities / assets21.2%
Debt / equity0.06x
Current ratio6.15x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $85.21M | $37,000 |
| R&D expense | $195.70M | $141.30M |
| SG&A expense | $49.06M | $46.58M |
| Operating income | -$159.55M | -$187.84M |
| Income tax | $0 | $0 |
| Net income | -$140.11M | -$160.87M |
| EBITDA | -$154.85M | -$183.19M |
| EPS (basic) | -2.42 | -2.98 |
| EPS (diluted) | -2.42 | -2.98 |
| Weighted avg. shares (diluted) | 57.93M | 53.94M |
| Balance sheet | ||
| Cash & equivalents | $60.24M | $149.34M |
| Short-term investments | $342.41M | $275.54M |
| Current assets | $413.13M | $434.93M |
| PP&E, net | $14.87M | $19.53M |
| Total assets | $566.71M | $560.38M |
| Current liabilities | $43.98M | $29.15M |
| Long-term debt | $0 | — |
| Total debt | $0 | — |
| Total liabilities | $61.05M | $49.78M |
| Shareholders' equity | $505.66M | $510.61M |
| Net debt | -$60.24M | — |
| Shares outstanding | 57.61M | 45.79M |
| Cash flow statement | ||
| Operating cash flow | -$109.08M | -$134.59M |
| Capital expenditure | $536,000 | $3.79M |
| Free cash flow | -$109.62M | -$138.37M |
| Investing cash flow | -$92.97M | -$302.44M |
| Financing cash flow | $112.96M | $337.25M |
| Depreciation & amortization | $4.69M | $4.65M |
| Stock-based compensation | $22.02M | $26.12M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.